

Commercializing University Results

Robert A. Lodder, Ph.D.

Professor, University of Kentucky

President, Spherix, Inc.



<http://www.pharm.uky.edu/>

FDA Granted Market Clearance for the LipiScan™ Coronary Imaging System – April 29, 2008





InfraReDx is dedicated to improving Health Care through the application of Photonics to Medicine.

Corporate Introduction	Meet InfraReDx - company profile, employment opportunities, and more .	
Technology Development	Click here for information on InfraReDx Technology Development.	
Vulnerable Plaque	Learn more about this disease that is now suspected to cause the majority of heart attacks.	

[Company Profile](#) | [Vulnerable Plaque](#) | [Technology Development](#) | [Career Opportunities](#) | [Site Map](#)

Lead VC: Sanderling Biomedical \$56M



[OUR COMPANY](#)

[OUR PRODUCTS](#)

[VULNERABLE PLAQUE](#)


[INVESTOR RELATIONS](#)

pre•scent\ˈpresh-ant\ adj: knowing beforehand

Prevent Heart Attacks with Vulnerable Plaque Technology

... what is vulnerable plaque?

...who is vulnerable?



[Introduction](#)



[Cause of
Heart Attack](#)



[Plaque
Detection](#)



[Optographic
Catheter™](#)



[HOME](#)

[SITE MAP](#)

[PRIVACY STATEMENT](#)

[LEGAL STATEMENT](#)

[CONTACT PRESCIENT MEDICAL](#)

Lead VC: Spencer Trask

\$27M + Series B



[Government](#)
[Healthcare](#)
[Reservations](#)
[Business Solutions](#)
[BioSpherix](#)

Contact Centers,
e-Government,
IT Services,
Contract Vehicles

Contact Centers,
Clinical Trial Support,
Withdrawal Support

Camp reservations,
Tour tickets,
Inventory
Management,
Enterprise Solutions

IT Services,
e-Business,
Knowledge
management

Naturlose,
Mars Research,
Purchase
Carbohydrates

- [OVERVIEW](#)
- [PRESS RELEASES](#)
- [ANNUAL REPORT](#)
- [CAREERS](#)
- [CONTACT US](#)
- [SEC FILING](#)

OUR HOT SPOTS




HEADLINES

- ◆ TAGATOSE TAKES MAJOR STEP TOWARD APPROVAL IN EUROPE
- ◆ SPHERIX EXPANDS CALL CENTER FOR HURRICANE RELIEF EFFORT
- ◆ SPHERIX'S STOCKHOLDERS' EQUITY BACK ABOVE \$10 MILLION
- ◆ SPHERIX ANNOUNCES SECOND QUARTER GROWTH
- ◆ WHAT ARE MARTIANS LIKE?


2007 Annual Sales \$24M, 600+ employees, Public Float (12 million sh)

D-Tagatose Mechanisms of Action in Digestive Tract



Currently in Phase III clinical trials at sites across the US

D-Tagatose Mechanisms of Action in Liver



The net effects of the regulation of these enzymes are to increase glycogen synthesis, and to decrease glycogen utilization.

Phase 2 Dose Ranging

Current Enrollment

- **38 patients randomized (23 at the time of the last board meeting)**
- **US-based study**
- **Slight delay reported**
- **Complete before the phase III**
- **Enrollment final Q2 of 2009**

Status of Phase III

- **Global enrollment goal 500 patients randomized by March 31, 2009**
 - 250 United States yielding 150 completers
 - 250 India yielding 180 completers
 - 330 Completers between 2 countries
- **Current Enrollment**
 - Nearly 400 patients screened
 - 169 randomized (104 currently enrolled)
 - 65 dropouts/early terminations
 - Approx 30 patients in the lead in period
 - 200 screen fails

India Timeline

- **Goals**
 - 25 sites/250 patients by March 31, 2009
 - 180 completers
- **Work has begun**
 - Site identification and qualification visits are occurring
 - Regulatory filing to occur this week
 - First patient screened October 31, 2008

Interface Issues

Grants don't scale

Departmental / disciplinary barriers

Interest in entrepreneurship

Accounting, SOX

TTO time constant

Flattening relationship to “bypassing”